

January 2026

Dear MicroScan System Customer,

Beckman Coulter Inc. is pleased to announce the launch of the LabPro V5.03 Panel Update-11.

This LabPro version introduces six new MicroScan panels:

- Neg MIC 65 (D18443)
- Neg Combo 104 (D18444)
- Neg Combo 105 (D18445)
- Neg Combo 106 (D18446)
- Pos Combo 50 (D18447)
- Pos MIC 41 (D18448)

Key features of the new Gram-negative panels are:

- The new naming convention is Neg Combo panels.
 - The panels will still contain both systemic and urine antimicrobial agents but will no longer be referred to as Neg Urine Combos.
- Updated formulation and interpretive breakpoints for Cefepime.
- Dilution coverage for the following antimicrobial agents to accommodate recent and upcoming FDA and CLSI breakpoint changes:
 - Amikacin
 - Ciprofloxacin
 - Gentamicin
 - Levofloxacin
 - Piperacillin-tazobactam
 - Tobramycin

Key features of the new Gram-positive panels are:

- Updated formulation and interpretive breakpoints for Daptomycin.
- Dilution coverage for the following antimicrobial agents to accommodate recent and upcoming FDA and CLSI breakpoint changes:
 - Ceftaroline
 - Oxacillin

Key features of the updated software are:

- Updated interpretive breakpoints for Gram-negative Aztreonam for new and existing panels
- The addition of the interpretive criteria, “Susceptible Dose Dependent (SDD)”
- The addition of system-defined drug suppression rules which may be used for organism groups where performance has not been established or cleared for reporting in the United States, interpretive criteria is not available, or insufficient numbers of organisms have been tested.
- Updated therapy reporting for staphylococci to MIC-only reporting for the following antimicrobial agents to better align with CLSI guidelines which no longer provide breakpoints:

Abbreviation	Description
Aug	Amoxicillin-clavulanic acid
A/S	Ampicillin-sulbactam
Cf	Cephalothin
Cfz	Cefazolin
Crm	Cefuroxime
Cft	Cefotaxime
Cax	Ceftriaxone
Cpe	Cefepime
Imp	Imipenem
Mer	Meropenem
P/T	Piperacillin-tazobactam

In preparation for the launch, please refer to Tables 1 through 5 for updated panel information that may assist you as you work with your Laboratory Information System (LIS) and pharmacy contacts. The updated formulations and interpretive breakpoints in this launch have received clearance from the U.S. Food and Drug Administration (FDA) for in vitro diagnostic use.

In addition, with the launch of new panels that better align with reporting needs, we have identified panels that will be phased out over the next 12 – 24 months. Please refer to Table 6 for the list of panels targeted for phasing out and suggested replacements. Additional communications will be sent as we move closer to the phase out date for each panel.

Best Regards,

Beckman Coulter Microbiology Marketing Team

Table 1: Gram Negative Panel Configurations

Antimicrobial Agent	D18443 Neg MIC 65	D18444 Neg Combo 104	D18445 Neg Combo 105	D18446 Neg Combo 106
Amikacin	4-32	--	4-32	--
Amoxicillin/K Clavulanate	8/4-16/8	8/4-16/8	--	8/4-16/8
Ampicillin	8-16	8-16	8-16	8-16
Ampicillin/Sulbactam	8/4-16/8	8/4-16/8	8/4-16/8	--
Aztreonam	4-16	--	--	--
Cefazolin	2-16	2-16	2-16	2-16
Cefepime	2-16	2-16	2-16	2-16
Cefotaxime	2,16	2,16	2,16	2,16
Cefoxitin	8-16	--	8-16	8-16
Ceftazidime	1,4-16	1,4-16	1,4-16	1,4-16
Ceftazidime/Avibactam	4/4-16/4	8/4-16/4	8/4-16/4	8/4-16/4
Ceftolozane/Tazobactam	2/4-8/4	--	2/4-8/4	--
Ceftriaxone	1-2,8,32	1-2	1-2	1-2
Cefuroxime	4-16	4-16	--	4-16
Ciprofloxacin	0.06-2	0.25-2	--	0.25-2
Ertapenem	0.5-1	0.5-1	0.5-1	0.5-1
ESBL Confirmation	Yes	Yes	Yes	Yes
Gentamicin	1-8	2-8	--	2-8
Imipenem	1-8	--	--	1-8
Levofloxacin	0.12-2	0.5-4	0.5-4	0.5-4
Meropenem	1-8	1-8	1-8	--
Meropenem/Vaborbactam	4/8-16/8	--	4/8-16/8	--
Minocycline	1-8	--	--	2-8
Nitrofurantoin	32-64	32-64	32-64	32-64
Piperacillin/Tazobactam	8/4-64/4	8/4-64/4	8/4-64/4	8/4-64/4
Tetracycline	4-8	4-8	4-8	4-8
Tobramycin	1-8	1-8	1-8	--
Trimethoprim/Sulfamethoxazole	0.5/9.5-2/38	2/38	2/38	2/38

Table 2: Gram Positive Panel Configurations

Antimicrobial Agent	D18447 Pos Combo 50	D18448 Pos MIC 41
Ampicillin	0.25-0.5,8	0.25-8
Azithromycin	2-4	0.5-4
Cefoxitin Screen	4	4
Ceftaroline	0.5-4	0.25-4
Chloramphenicol	--	8-16
Ciprofloxacin	1-2	0.5-4
Clindamycin	0.25-2	0.25-4
Daptomycin	1-4	0.5-4
Erythromycin	0.25-4	0.25-4
Gentamicin	4-8	1-8
Gentamicin Synergy Screen	500	500
Inducible Clindamycin	4/0.5	4/0.5
Levofloxacin	1-4	0.5-4
Linezolid	2-4	0.5-4
Moxifloxacin	--	0.5-4
Nitrofurantoin	32-64	32-64
Oxacillin	0.25-4	0.25-4
Penicillin	0.06-8	0.06-8
Rifampin	1-2	1-2
Streptomycin Synergy Screen	1000	1000
Synercid	--	0.5-2
Tetracycline	2-8	1-8
Tigecycline	0.25-1	0.25-1
Trimethoprim/Sulfamethoxazole	0.5/9.5-2/38	0.5/9.5-2/38
Vancomycin	0.5-16	0.25-16

Table 3: Gram-Negative Aztreonam breakpoints

Reporting Group	Susceptible	Intermediate	Resistant
Enterobacterales	≤4	8	≥16
<i>P. aeruginosa</i>	≤8	16	≥32

Table 4: Gram-Negative Cefepime breakpoints

Reporting Group	Susceptible	Susceptible Dose Dependent	Intermediate	Resistant
<i>Aeromonas</i> spp.	≤2	--	4-8	≥16
Enterobacterales	≤2	4-8	--	≥16
<i>P. aeruginosa</i>	≤8	--	16	≥32

Table 5: Gram-Positive Daptomycin breakpoints

Reporting Group	Susceptible	Susceptible Dose Dependent	Intermediate	Resistant
<i>Staphylococcus</i> spp.	≤1	--	--	--
<i>Enterococcus</i> spp. other than <i>E.</i> <i>faecium</i>	≤2	--	4	≥8
<i>E. faecium</i>	--	≤4	-	≥8

Table 6: Panel Obsoletions and Suggested Replacements

Catalog #	Description	Suggested Replacement	Additions and Improvements
B1017-211	Pos Combo 33	D18447 Pos Combo 50	Azithromycin, Ceftaroline, Updated Daptomycin formulation with current FDA breakpoints, Tigecycline, Updated Vancomycin formulation with 16-18 hour read for all applicable organisms and improved <i>S. aureus</i> performance.
B1017-212	Pos MIC 29	D18448 Pos MIC 41	Azithromycin, Ceftaroline, Updated Daptomycin formulation with current FDA breakpoints, Tigecycline, Updated Vancomycin formulation with 16-18 hour read for all applicable organisms and improved <i>S. aureus</i> performance.
B1017-214	Pos Combo 34	D18447 Pos Combo 50	Azithromycin, Ceftaroline, Daptomycin formulation with current FDA breakpoints, Tigecycline, Updated Vancomycin formulation with 16-18 hour read for all applicable organisms and improved <i>S. aureus</i> performance.
B1017-218	Pos Combo 44	D18447 Pos Combo 50	Daptomycin formulation with current FDA breakpoints, Oxacillin 0.5 dilution, Tigecycline
B1017-220	Pos Combo 46	D18447 Pos Combo 50	Azithromycin, Ciprofloxacin, Updated Daptomycin formulation with current FDA breakpoints

Table 6: Panel Obsoletions and Suggested Replacements (Continued)

Catalog Number	Description	Suggested Replacement	Additions and Improvements
B1017-414	Neg Urine Combo 61	D18444 Neg Combo 104	Amoxicillin-K Clavulanate, Updated Cefepime formulation with current FDA breakpoints, Ceftazidime-avibactam, Tetracycline, lower dilutions for Cefazolin, Ciprofloxacin, Ertapenem, Gentamicin, Levofloxacin, Piperacillin-tazobactam, and Tobramycin
		D18445 Neg Combo 105	Updated Cefepime formulation with current FDA breakpoints, Ceftazidime-avibactam, Ceftolozane-tazobactam, Meropenem-vaborbactam, Tetracycline, lower dilutions for Amikacin, Cefazolin, Ciprofloxacin, Ertapenem, Levofloxacin, Piperacillin-tazobactam and Tobramycin
		D18446 Neg Combo 106	Amoxicillin-K Clavulanate, Updated Cefepime formulation with current FDA breakpoints, Ceftazidime-avibactam, Updated Imipenem formulation, Minocycline, lower dilutions for Cefazolin, Ciprofloxacin, Levofloxacin, and Piperacillin-tazobactam
B1017-423	Neg Urine Combo 73	D18444 Neg Combo 104	Updated Cefepime formulation with current FDA breakpoints, Ceftazidime-avibactam, Meropenem, lower dilutions for Ciprofloxacin, Levofloxacin, Piperacillin-tazobactam and Tobramycin
		D18445 Neg Combo 105	Updated Cefepime formulation with current FDA breakpoints, Cefoxitin, Ceftazidime-Avibactam, Ceftolozane-tazobactam, Meropenem, Meropenem-vaborbactam, lower dilutions for Amikacin, Ciprofloxacin, Levofloxacin, Piperacillin-tazobactam and Tobramycin
		D18446 Neg Combo 106	Updated Cefepime formulation with current FDA breakpoints, Cefoxitin, Ceftazidime-avibactam, Updated Imipenem formulation, Minocycline, lower dilutions for Ciprofloxacin, Levofloxacin, Piperacillin-tazobactam

Table 6: Panel Obsoletions and Suggested Replacements (Continued)

Catalog Number	Description	Suggested Replacement	Additions and Improvements
B1017-424	Neg MIC 45	D18443 Neg MIC 65	Updated Cefepime formulation with current FDA breakpoints, Ceftazidime-avibactam, Ceftolozane-tazobactam, Meropenem-vaborbactam, Minocycline, Tetracycline, Updated Imipenem formulation, lower dilutions for Amikacin, Ciprofloxacin, Levofloxacin and Trimethoprim-sulfamethoxazole
B1017-432	Neg MIC 53	D18443 Neg MIC 65	Updated Cefepime formulation with current FDA breakpoints, Meropenem-vaborbactam, lower dilutions for Amikacin, Ciprofloxacin, Gentamicin, Levofloxacin, Minocycline, Tobramycin and Trimethoprim-sulfamethoxazole
B1017-433	Neg MIC 54	D18443 Neg MIC 65	Updated Cefepime formulation with current FDA breakpoints, Cefoxitin, Ceftolozane-tazobactam, Meropenem-vaborbactam, Tetracycline, Updated Imipenem formulation, lower dilutions for Amikacin, Ciprofloxacin, Levofloxacin, Minocycline and Trimethoprim-sulfamethoxazole
B1017-434	Neg Urine Combo 84	D18444 Neg Combo 104	Amoxicillin-K Clavulanate, Updated Cefepime formulation with current FDA breakpoints, Ceftazidime-avibactam, lower dilutions for Ciprofloxacin, Gentamicin, Levofloxacin, Piperacillin-tazobactam and Tobramycin
		D18445 Neg Combo 105	Updated Cefepime formulation with current FDA breakpoints, Ceftazidime-avibactam, Ceftolozane-tazobactam, Meropenem-vaborbactam, lower dilutions for Amikacin, Levofloxacin, Piperacillin-tazobactam and Tobramycin
		D18446 Neg Combo 106	Amoxicillin-K Clavulanate, Updated Cefepime formulation with current FDA breakpoints, Ceftazidime-avibactam, Minocycline, lower dilutions for Ciprofloxacin, Gentamicin, Levofloxacin, and Piperacillin-tazobactam

Table 6: Panel Obsoletions and Suggested Replacements (Continued)

Catalog Number	Description	Suggested Replacement	Additions and Improvements
B1017-435	Neg Urine Combo 85	D18444 Neg Combo 104	Updated Cefepime formulation with current FDA breakpoints, Ceftazidime-avibactam, Cefuroxime, lower dilutions for Ciprofloxacin, Gentamicin, Levofloxacin, Piperacillin-tazobactam and Tobramycin
		D18445 Neg Combo 105	Updated Cefepime formulation with current FDA breakpoints, Ceftoxitin, Ceftazidime-avibactam, Ceftolozane-tazobactam, Meropenem-vaborbactam, lower dilutions for Amikacin, Levofloxacin, Piperacillin-tazobactam, and Tobramycin
		D18446 Neg Combo 106	Updated Cefepime formulation with current FDA breakpoints, Ceftoxitin, Ceftazidime-avibactam, lower dilutions for Ciprofloxacin, Gentamicin, Levofloxacin, and Piperacillin-tazobactam
B1017-436	Neg Urine Combo 86	D18444 Neg Combo 104	Amoxicillin-K Clavulanate, Updated Cefepime formulation with current FDA breakpoints, Cefuroxime, lower dilutions for Ciprofloxacin, Gentamicin, Levofloxacin, Piperacillin-tazobactam, and Tobramycin
		D18445 Neg Combo 105	Updated Cefepime formulation with current FDA breakpoints, Ceftolozane-tazobactam, Meropenem-vaborbactam, lower dilutions for Amikacin, Levofloxacin, Piperacillin-tazobactam and Tobramycin
		D18446 Neg Combo 106	Amoxicillin-K Clavulanate, Updated Cefepime formulation with current FDA breakpoints, Cefuroxime, Minocycline, lower dilutions for Ciprofloxacin, Gentamicin, Levofloxacin, Piperacillin-and tazobactam
B1027-201	MICroSTREP plus 1	B1027-202 MICroSTREP plus 2	Clarithromycin, Daptomycin, Linezolid, Moxifloxacin